- Home
- NXTC vs GROW Comparison
NXTC vs GROW Comparison
Compare NXTC & GROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- GROW
- Stock Information
- Founded
- NXTC 2015
- GROW 1968
- Country
- NXTC United States
- GROW United States
- Employees
- NXTC N/A
- GROW N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- GROW Investment Managers
- Sector
- NXTC Health Care
- GROW Finance
- Exchange
- NXTC Nasdaq
- GROW Nasdaq
- Market Cap
- NXTC 31.6M
- GROW 32.9M
- IPO Year
- NXTC 2019
- GROW N/A
- Fundamental
- Price
- NXTC $0.89
- GROW $2.42
- Analyst Decision
- NXTC Strong Buy
- GROW
- Analyst Count
- NXTC 2
- GROW 0
- Target Price
- NXTC $4.00
- GROW N/A
- AVG Volume (30 Days)
- NXTC 218.5K
- GROW 26.2K
- Earning Date
- NXTC 11-07-2024
- GROW 02-06-2025
- Dividend Yield
- NXTC N/A
- GROW 3.71%
- EPS Growth
- NXTC N/A
- GROW N/A
- EPS
- NXTC N/A
- GROW 0.12
- Revenue
- NXTC N/A
- GROW $10,008,000.00
- Revenue This Year
- NXTC N/A
- GROW N/A
- Revenue Next Year
- NXTC N/A
- GROW N/A
- P/E Ratio
- NXTC N/A
- GROW $19.98
- Revenue Growth
- NXTC N/A
- GROW N/A
- 52 Week Low
- NXTC $0.87
- GROW $2.38
- 52 Week High
- NXTC $2.57
- GROW $3.05
- Technical
- Relative Strength Index (RSI)
- NXTC 22.88
- GROW 46.77
- Support Level
- NXTC $1.06
- GROW $2.40
- Resistance Level
- NXTC $1.21
- GROW $2.45
- Average True Range (ATR)
- NXTC 0.10
- GROW 0.04
- MACD
- NXTC -0.02
- GROW 0.00
- Stochastic Oscillator
- NXTC 5.21
- GROW 25.00
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
About GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.